Novo Nordisk A/S
MIC-1 and GLP-1 for use in the treatment of obesity
Last updated:
Abstract:
The invention relates to MIC-1 compounds for use in the prevention and/or treatment of obesity, wherein the MIC-1 compounds is administered simultaneously, separately or sequentially with a GLP-1 compound.
Status:
Grant
Type:
Utility
Filling date:
10 Sep 2018
Issue date:
1 Mar 2022